Targeting Alzheimer's with Novel Therapeutics

Cambridge Healthtech Institute's Eighth Annual
World Pharmaceutical Congress
June 10-11, 2009   Philadelphia, PA

Cambridge Healthtech Institute's 8th annual World Pharmaceutical Congress takes place in Philadelphia this year and will feature the inaugural Targeting Alzheimer's with Novel Therapeutics conference from June 10-11.

This inaugural Alzheimer's conference features the leading developers of cutting edge therapeutics for Alzheimer's disease, including perispinal etanercept, Rember™, and Dimebon™.

Edward Tobinick, M.D., Director of the Institute for Neurological Research®, a private medical group, inc.(INR®) will present TNF Modulation for Treatment of Alzheimer's Disease, a discussion of the use of perispinal etanercept for Alzheimer's and related forms of dementia.

Claude M. Wischik, Ph.D., Professor Old Age Psychiatry University of Aberdeen and Chairman TauRx Therapeutics will present Potential Efficacy of Tau Aggregation Inhibitor Therapy with Rember™ in Alzheimer's Disease and

Dimebon: Turning an Old Drug to a New Use will be presented by Lynn Seely, M.D., Chief Medical Officer, Medivation, Inc.

Holding promise are Rember™ and Dimebon™ which are experimental drugs not presently available to the public for therapeutic use.  Perispinal etanercept, a unique, patented[1] immunomodulatory approach developed by Dr. Tobinick at the INR®, is currently available to patients at the INR® Los Angeles and from INR trained physicians in North America, Europe and Africa.

The major pharmaceutical giants also searching for a treatment for the over 5 million Americans suffering from Alzheimer's disease will be represented at the Targeting Alzheimer's with Novel Therapeutics conference by:

Chairperson Timothy A. Esbenshade, Ph.D., Senior Group Leader, Neuroscience Research, Abbott Laboratories

Scott D. Bembenek, Ph.D.,  Senior Scientist, Computer Aided Drug Discovery, Johnson & Johnson

Michael L. Hutton, Ph.D., Leader, Alzheimer's Group, Merck Research Laboratories

For further information, please visit:

Institute for Neurological Research, a private medical group, inc.  Los Angeles, California website

World Pharmaceutical Congress

[1] Multiple issued and pending U.S. and international patents, including, but not limited to, US patents 6,982,089 and 7,214,658.